Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2016115475 - FORMULATIONS D'ANTICORPS ANTI-CD40


Avertissement La version image (PDF) disponible dans PATENTSCOPE est la version officielle. Cette version HTML en ligne est fournie pour aider les utilisateurs. Malgré le grand soin apporté à la compilation pour assurer une représentation précise et exacte des données figurant sur le document/les images imprimés, des erreurs et/ou des omissions ne peuvent pas être exclues en raison des processus de transmission et de conversion de données et des limitations inhérentes aux processus de traduction (éventuellement) automatique utilisés. Les liens hypertexte suivis de ce symbole sont associés à des ressources externes qui ne sont pas contrôlées par l'OMPI. L'OMPI décline toute responsabilité concernant les points mentionnés ci-dessus.

INTERNATIONAL SEARCH REPORT (ISR)
Part 1:  1  2  3  4  5  6          Part 2:  A  B  C  D  E 
International application No. Applicant's or agent's file reference
PCT/US2016/013627 B1152.70046
International filing date (day/month/year) (Earliest) Priority Date (day/month/year)
15 January 2016 18 January 2015
Applicant
BIOGEN MA INC.
FOR FURTHER ACTION: See Form PCT/ISA/220 as well as, where applicable, item 5 below.
This international search report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.
It is also accompanied by a copy of each prior art document cited in this report.
1. Basis of the report
a. With regard to the language, the international search was carried out on the basis of:
the international application in the language in which it was filed.
a translation of the international application into                                          which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
b.
This international search report has been established taking into account the rectification of an obvious mistake authorized by or notified to this Authority under Rule 91 (Rule 43.6bis(a)).
c.
With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of a sequence listing:
2. Certain claims were found unsearchable
3. Unity of invention is lacking
This International Searching Authority found multiple inventions in this international application, as follows:
1. claims: 1-19, 21-34(completely); 20, 54(partially)
An anti-CD40 antibody formulation comprising a buffer system at pH 5.0-6.5, and possibly arginine (140-160 mM), wherein the buffer is citrate (10-30 mM).
2. claims: 35-53, 55-68(completely); 20, 54(partially)
An anti-CD40 antibody formulation comprising a buffer system at pH 5.0-6.5, and possibly arginine (140-160 mM), wherein the buffer is histidine (10-30 mM).
1.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2.
As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3.
As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4.
No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
The additional search fees were accompanied by the applicant’s protest and, where applicable, the payment of a protest fee.
The additional search fees were accompanied by the applicant’s protest but the applicable protest fee was not paid within the time limit specified in the invitation.
No protest accompanied the payment of additional search fees.
4. Title of the invention
The text is approved as submitted by the applicant.
The text has been established by this Authority to read as follows:
5. Abstract
The text is approved as submitted by the applicant.
The text has been established, according to Rule 38.2, by this Authority as it appears in Box No. IV. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.
6. Drawings
a.
The figure of the drawings to be published with the abstract is Figure No.     4C    
as suggested by the applicant.
as selected by this Authority, because the applicant failed to suggest a figure.
as selected by this Authority, because this figure better characterizes the invention.
b.
none of the figures is to be published with the abstract.

A. CLASSIFICATION OF SUBJECT MATTER

     A61K 39/395 (2006.01)i; A61K 47/12 (2006.01)i; A61K 47/18 (2006.01)i
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols):
     A61K
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched:
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used):
EPO-Internal, BIOSIS, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No.
(1)
X
US 2011002934 A1 (LUQMAN MOHAMMAD [US] ET AL) 06 January 2011 (2011-01-06)
1
Y
paragraph [0188]
2-34,54
(2)
X
US 2009304706 A1 (LU XIAOFENG [US] ET AL) 10 December 2009 (2009-12-10)
1
Y
paragraphs [0038], [0065], [0066]; examples
2-34,54
(3)
E
WO 2016028810 A1 (BIOGEN MA INC [US]) 25 February 2016 (2016-02-25)
1-34,54
page 32, line 4 - page 33, line 5; example 35
page 74, line 25 - page 75, line 8
page 76, lines 11-23
(4)
X
US 2004197324 A1 (LIU JUN [US] ET AL) 07 October 2004 (2004-10-07)
20,35-68
paragraphs [0012], [0014], [0032]; examples
(5)
A
WO 03105894 A1 (MEDIMMUNE INC [US]; OLIVER CYNTHIA N [US]; SHANE ERICA [US]; ISSAACS B) 24 December 2003 (2003-12-24)
1-68
page 42, lines 31-34; example 1
*
Special categories of cited documents:
"A"
document defining the general state of the art which is not considered to be of particular relevance
"D"
document cited by the applicant in the international application
"E"
earlier application or patent but published on or after the international filing date
"L"
document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O"
document referring to an oral disclosure, use, exhibition or other means
"P"
document published prior to the international filing date but later than the priority date claimed
"T"
later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X"
document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y"
document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&"
document member of the same patent family

D. INFORMATION ON PATENT FAMILY MEMBERS

Patent document cited in search report Publication date
(day/month/year)
Patent family member(s) Publication date
(day/month/year)
US 2011002934 A1
06 January 2011
AU 2008323815 A1
BR PI0820407 A2
CA 2705263 A1
CN 101970003 A
EP 2211902 A1
JP 5559695 B2
JP 2011503098 A
KR 20100088621 A
RU 2010123363 A
US 2011002934 A1
WO 2009062054 A1
14 May 2009
26 May 2015
14 May 2009
09 February 2011
04 August 2010
23 July 2014
27 January 2011
09 August 2010
20 December 2011
06 January 2011
14 May 2009
US 2009304706 A1
10 December 2009
AR 060487 A1
AU 2007240507 A1
BR PI0710826 A2
CA 2649907 A1
CN 101426817 A
CR 10379 A
EA 200802135 A1
EC SP088903 A
EP 2019841 A2
GE P20125628 B
GT 200700034 A
HN 2008001572 A
JP 5290152 B2
JP 2009534401 A
JP 2013129673 A
KR 20090009204 A
MA 30470 B1
ME P39508 A
NZ 571757 A
SM AP200800064 A
SV 2008003071 A
TW 200808349 A
UA 94264 C2
US 2009304706 A1
US 2015110783 A1
WO 2007124299 A2
18 June 2008
01 November 2007
23 August 2011
01 November 2007
06 May 2009
07 January 2009
28 April 2009
27 February 2009
04 February 2009
10 September 2012
25 January 2008
08 June 2011
18 September 2013
24 September 2009
04 July 2013
22 January 2009
01 June 2009
10 February 2011
12 January 2012
26 November 2008
01 February 2010
16 February 2008
26 April 2011
10 December 2009
23 April 2015
01 November 2007
WO 2016028810 A1
25 February 2016
NONE
US 2004197324 A1
07 October 2004
AR 043826 A1
AT 480567 T
AU 2004229335 A1
AU 2010200784 A1
BR PI0403964 A
CA 2519408 A1
CL 2004000731 A1
CL 2013000142 A1
CN 1798575 A
CN 102258464 A
CO 5660273 A2
CY 1111232 T1
DK 1610820 T3
EC SP056142 A
EP 1610820 A1
EP 2335725 A1
ES 2349779 T3
HK 1085933 A1
HR P20050934 A2
IL 170866 A
JP 4869064 B2
JP 5449268 B2
JP 2007524602 A
JP 2011246484 A
KR 20060017583 A
KR 20110067067 A
MA 27773 A1
MX PA05010555 A
NZ 542964 A
PE 03942005 A1
PT 1610820 E
RU 2332986 C2
TW I357820 B
US 2004197324 A1
US 2007053900 A1
US 2009280129 A1
US 2012064086 A1
US 2015225485 A1
WO 2004091658 A1
ZA 200507757 A
17 August 2005
15 September 2010
28 October 2004
25 March 2010
01 March 2005
28 October 2004
20 May 2005
01 April 2013
05 July 2006
30 November 2011
31 July 2006
11 June 2015
29 November 2010
19 April 2006
04 January 2006
22 June 2011
11 January 2011
08 July 2011
30 June 2006
30 September 2013
01 February 2012
19 March 2014
30 August 2007
08 December 2011
24 February 2006
20 June 2011
01 February 2006
09 March 2006
30 June 2008
19 June 2005
16 December 2010
10 September 2008
11 February 2012
07 October 2004
08 March 2007
12 November 2009
15 March 2012
13 August 2015
28 October 2004
31 January 2007
WO 03105894 A1
24 December 2003
AT 476198 T
AU 2003245515 A1
AU 2008202925 A1
AU 2011202179 A1
CA 2489632 A1
CY 1110873 T1
DK 1531862 T3
DK 2206516 T3
EP 1531862 A1
EP 2206516 A1
EP 2327421 A1
ES 2350754 T3
ES 2539039 T3
HK 1145992 A1
JP 4598517 B2
JP 5443291 B2
JP 5666631 B2
JP 2006501168 A
JP 2010270136 A
JP 2013100342 A
PT 1531862 E
PT 2206516 E
SI 1531862 T1
SI 2206516 T1
US 2006034827 A1
US 2007048332 A1
US 2008286270 A1
US 2011027272 A1
US 2012039876 A1
US 2012321616 A1
US 2014056877 A1
US 2015086544 A1
WO 03105894 A1
15 August 2010
31 December 2003
24 July 2008
02 June 2011
24 December 2003
10 June 2015
29 November 2010
22 June 2015
25 May 2005
14 July 2010
01 June 2011
26 January 2011
25 June 2015
22 January 2016
15 December 2010
19 March 2014
12 February 2015
12 January 2006
02 December 2010
23 May 2013
08 November 2010
20 July 2015
28 February 2011
30 October 2015
16 February 2006
01 March 2007
20 November 2008
03 February 2011
16 February 2012
20 December 2012
27 February 2014
26 March 2015
24 December 2003
Name and mailing address of the ISA/:
European Patent Office
P.B. 5818, Patentlaan 2, 2280 HV Rijswijk,
Netherlands
Telephone No. (+31-70)340-2040
Facsimile No. (+31-70)340-3016
Date of the actual completion of the international search:
01 June 2016
Date of mailing of the international search report:
10 June 2016
Authorized officer:
Giménez Miralles, J
Top    Part 1: 1 2 3 4 5 6         Part 2: A B C D E